Paraneoplastic nervous system syndromes

Kurt A. Jaeckle

Research output: Contribution to journalReview article

5 Citations (Scopus)

Abstract

Recent progress in the understanding of the paraneoplastic neurologic syndromes has included further deliniation of the clinical syndromes and their treatment, attempts at standardization of the diagnostic nomenclature, investigations of pathogenetic mechanisms, and molecular characterization of the paraneoplastic antigens with implications as to their biologic relevance. Despite more than 30 years of investigation, the pathogenesis of these presumably autoimmune conditions remains unclear. Furthermore, no effective therapy has been identified for these conditions, with the possible exception of the opsoclonus-myoclonus ataxia and Lambert-Eaton myasthenic syndromes. Future investigations must focus on the disrupted genetic regulatory events involved in generation and propagation of the autoimmune response, antigen presentation and processing; target cell destruction, and consideration of alternative pathologic causes. Effective management strategies are most likely to develop from a better understanding of the disease pathogenesis, the development of animal model systems, and a creative look beyond the usual therapies employed in autoimmune conditions.

Original languageEnglish (US)
Pages (from-to)204-208
Number of pages5
JournalCurrent Opinion in Oncology
Volume8
Issue number3
DOIs
StatePublished - Jan 1 1996
Externally publishedYes

Fingerprint

Nervous System Paraneoplastic Syndromes
Antigen Presentation
Opsoclonus-Myoclonus Syndrome
Lambert-Eaton Myasthenic Syndrome
Autoimmunity
Terminology
Therapeutics
Animal Models
Antigens

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Jaeckle, Kurt A. / Paraneoplastic nervous system syndromes. In: Current Opinion in Oncology. 1996 ; Vol. 8, No. 3. pp. 204-208.
@article{28c5a6d351b0405e844517d06872b44b,
title = "Paraneoplastic nervous system syndromes",
abstract = "Recent progress in the understanding of the paraneoplastic neurologic syndromes has included further deliniation of the clinical syndromes and their treatment, attempts at standardization of the diagnostic nomenclature, investigations of pathogenetic mechanisms, and molecular characterization of the paraneoplastic antigens with implications as to their biologic relevance. Despite more than 30 years of investigation, the pathogenesis of these presumably autoimmune conditions remains unclear. Furthermore, no effective therapy has been identified for these conditions, with the possible exception of the opsoclonus-myoclonus ataxia and Lambert-Eaton myasthenic syndromes. Future investigations must focus on the disrupted genetic regulatory events involved in generation and propagation of the autoimmune response, antigen presentation and processing; target cell destruction, and consideration of alternative pathologic causes. Effective management strategies are most likely to develop from a better understanding of the disease pathogenesis, the development of animal model systems, and a creative look beyond the usual therapies employed in autoimmune conditions.",
author = "Jaeckle, {Kurt A.}",
year = "1996",
month = "1",
day = "1",
doi = "10.1097/00001622-199605000-00006",
language = "English (US)",
volume = "8",
pages = "204--208",
journal = "Current Opinion in Oncology",
issn = "1040-8746",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

Paraneoplastic nervous system syndromes. / Jaeckle, Kurt A.

In: Current Opinion in Oncology, Vol. 8, No. 3, 01.01.1996, p. 204-208.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Paraneoplastic nervous system syndromes

AU - Jaeckle, Kurt A.

PY - 1996/1/1

Y1 - 1996/1/1

N2 - Recent progress in the understanding of the paraneoplastic neurologic syndromes has included further deliniation of the clinical syndromes and their treatment, attempts at standardization of the diagnostic nomenclature, investigations of pathogenetic mechanisms, and molecular characterization of the paraneoplastic antigens with implications as to their biologic relevance. Despite more than 30 years of investigation, the pathogenesis of these presumably autoimmune conditions remains unclear. Furthermore, no effective therapy has been identified for these conditions, with the possible exception of the opsoclonus-myoclonus ataxia and Lambert-Eaton myasthenic syndromes. Future investigations must focus on the disrupted genetic regulatory events involved in generation and propagation of the autoimmune response, antigen presentation and processing; target cell destruction, and consideration of alternative pathologic causes. Effective management strategies are most likely to develop from a better understanding of the disease pathogenesis, the development of animal model systems, and a creative look beyond the usual therapies employed in autoimmune conditions.

AB - Recent progress in the understanding of the paraneoplastic neurologic syndromes has included further deliniation of the clinical syndromes and their treatment, attempts at standardization of the diagnostic nomenclature, investigations of pathogenetic mechanisms, and molecular characterization of the paraneoplastic antigens with implications as to their biologic relevance. Despite more than 30 years of investigation, the pathogenesis of these presumably autoimmune conditions remains unclear. Furthermore, no effective therapy has been identified for these conditions, with the possible exception of the opsoclonus-myoclonus ataxia and Lambert-Eaton myasthenic syndromes. Future investigations must focus on the disrupted genetic regulatory events involved in generation and propagation of the autoimmune response, antigen presentation and processing; target cell destruction, and consideration of alternative pathologic causes. Effective management strategies are most likely to develop from a better understanding of the disease pathogenesis, the development of animal model systems, and a creative look beyond the usual therapies employed in autoimmune conditions.

UR - http://www.scopus.com/inward/record.url?scp=0029941760&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029941760&partnerID=8YFLogxK

U2 - 10.1097/00001622-199605000-00006

DO - 10.1097/00001622-199605000-00006

M3 - Review article

C2 - 8794147

AN - SCOPUS:0029941760

VL - 8

SP - 204

EP - 208

JO - Current Opinion in Oncology

JF - Current Opinion in Oncology

SN - 1040-8746

IS - 3

ER -